long-term monitoring gait analysis using a wearable device in daily lives of patients with parkinson’s disease: the efficacy of selegiline hydrochloride for gait disturbance
Clicks: 224
ID: 242426
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
224 views
52 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #198 of 263 articles by views in journal of photochemistry and photobiology a: chemistry
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 263 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
ObjectiveThe aim of this study was to assess quantitatively the gait disorders in the daily lives of patients with Parkinson’s disease (PD) using with a newly developed portable gait rhythmogram (PGR), which has a trunk-mounted acceleration sensor and automatic gait-detection algorithm.MethodsUsing the PGR, we recorded the daily walking profiles of 14 PD patients before and after the addition or increase in dose of an MAO-B inhibitor (selegiline, average dose: 4.0 mg/day) as part of their medicine regimen, and evaluated their gait using the unified Parkinson’s disease rating scale (UPDRS) and scores from a freezing of gait (FOG) questionnaire.ResultsBefore treatment with selegiline, the overall movements per 24 h was decreased below 0.41 m/s2 (mean − 1.5 SD) in eight patients. The mean gait acceleration was decreased below 1.94 m/s2 (mean − 2 SD) in 10 patients. The slope of the linear regression line was increased to 1.6 (mean + 1.5 SD) in eight patients. The cadence was increased to 124 steps/min (mean + 1.5 SD) in four patients. Based on continuous PGR recordings in the daily lives of the patients for 24 h, the addition or increase in dose of selegiline increased the amplitudes of gait accelerations in 4 of 10 patients (40.0%), widened the range of gait accelerations in 5 of 8 patients (62.5%), diminished the cadence in 4 of 4 patients (100%), and diminished the fluctuations in gait throughout the day in 12 of 14 patients (85.7%). The UPDRS III and FOG scores significantly improved after the addition or increase in dose of selegiline (p < 0.005, p < 0.01, respectively). However, changes in gait-related scores of UPDRS were not detected in six patients.ConclusionImprovements in the gait fluctuations of PD patients after the addition or increase in dose of selegiline were detected using the PGR in the daily lives of the patients for 24 h. The PGR had a higher sensitivity for detecting the improvements than UPDRS scores.
| Reference Key |
iijima2017frontierslong-term
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Mutsumi Iijima;Hiroshi Mitoma;Shinichiro Uchiyama;Kazuo Kitagawa |
| Journal | journal of photochemistry and photobiology a: chemistry |
| Year | 2017 |
| DOI |
10.3389/fneur.2017.00542
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.